FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission granted a marketing authorisation valid throughout the EU for Pegasys on 20 June 2002.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Pegasys, veljavno po vsej Evropski uniji, izdala 20. junija 2002.
English: The exact way alfa interferons work in viral diseases in not fully understood, but it is thought that they act as immunomodulators (substances that modify how the immune system, the body's defence system, works).
Slovenian: Točen način delovanja interferonov alfa pri virusnih boleznih ni popolnoma pojasnjen, domneva pa se, da delujejo kot imunomodulatorji (snovi, ki spreminjajo delovanje imunskega sistema, obrambnega sistema telesa).
English: Interferons are natural substances produced by the body that help it fight infections caused by viruses.
Slovenian: Interferoni so naravne snovi, ki jih proizvaja telo, da se z njimi brani pred okužbami, ki jih povzročajo virusi.
English: Alfa interferons may also block the multiplication of viruses.
Slovenian: Interferoni alfa morda tudi zavirajo razmnoževanje virusov.
English: This is a summary of the European public assessment report (EPAR) for Pegasys.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pegasys.
English: The adult dose is usually 180 micrograms but the children's dose varies depending on their height and weight.
Slovenian: Pri odraslih je običajni odmerek 180 mikrogramov, pri otrocih pa je odmerek odvisen od njihove telesne višine in mase.
English: What measures are being taken to ensure the safe and effective use of Pegasys?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pegasys?
English: The full EPAR for Pegasys can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pegasys je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Pegasys is an antiviral medicine used to treat:
Slovenian: Pegasys je protivirusno zdravilo, ki se uporablja za zdravljenje:
English: Other information about Pegasys
Slovenian: Druge informacije o zdravilu Pegasys
English: The most common side effects with Pegasys (seen in more than 1 patient in 10) are loss of appetite, headache, insomnia (difficulty sleeping), irritability, gut disorders (diarrhoea, nausea, and belly ache) rash, itching, hair loss, pain in muscles and joints, flu-like illness, reactions at the site of the injection and tiredness.
Slovenian: Najpogostejši neželeni učinki zdravila Pegasys (opaženi pri več kot 1 bolniku od 10) so izguba apetita, glavobol, nespečnost, razdražljivost, prebavne težave (driska, navzeja, bolečine v trebuhu), izpuščaj, srbenje, izpadanje las, bolečine v mišicah in sklepih, gripi podobna bolezen, reakcije na mestu injiciranja ter utrujenost.
English: This decreases the rate at which interferon is removed from the body and allows the medicine to be given less often.
Slovenian: Pegilacija zmanjšuje hitrost izločanja interferona iz telesa in omogoča manj pogosto dajanje zdravila.
English: Pegasys is given by injection under the skin in the abdomen (belly) or thigh - once a week for 48 weeks for hepatitis B and once a week for between 16 and 72 weeks for hepatitis C.
Slovenian: Zdravilo Pegasys se daje z injekcijo pod kožo v trebuh ali stegno, in sicer enkrat na teden 48 tednov pri hepatitisu B in enkrat na teden od 16 do 72 tednov pri hepatitisu C.
English: • chronic (long-term) hepatitis B in adults and children from 3 years of age
Slovenian: • kroničnega (dolgotrajnega) hepatitisa B pri odraslih in otrocih, starejših od treh let;
English: • chronic hepatitis C in adults and children from 5 years of age.
Slovenian: • kroničnega hepatitisa C pri odraslih in otrocih, starejših od pet let.
English: For hepatitis C, Pegasys has been studied on its own and in combination with other medicines.
Slovenian: Pri hepatitisu C so zdravilo Pegasys proučevali samostojno in v kombinaciji z drugimi zdravili.
English: Pegasys must not be used in people who are hypersensitive (allergic) to alpha interferons or any of the other ingredients.
Slovenian: Zdravila Pegasys ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) interferone alfa ali katero koli drugo sestavino zdravila.
English: It is not intended to provide practical advice on how to use Pegasys.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pegasys have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pegasys upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: For more information about treatment with Pegasys, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Pegasys preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the risks associated with Pegasys?
Slovenian: Kakšna tveganja so povezana z zdravilom Pegasys?
English: Among ‘HBeAgnegative' patients (those infected with a virus that has mutated and can be more difficult to treat), the clearance rate was 43% with Pegasys and 29% with lamivudine.
Slovenian: Med HBeAgnegativnimi bolniki (bolniki, okuženimi z virusom, ki je mutiral in ga je težje zdraviti) je bila stopnja očistka pri zdravilu Pegasys 43 %, pri lamivudinu pa 29 %.
English: What is Pegasys and what is it used for?
Slovenian: Kaj je zdravilo Pegasys in za kaj se uporablja?
English: Studies showed that Pegasys is effective at clearing signs of viral infection in adults and children with chronic hepatitis B or C. The European Medicines Agency (EMA) considered the benefits to outweigh the risks seen with this medicine and therefore recommended that it be given marketing authorisation.
Slovenian: Študije so pokazale, da zdravilo Pegasys učinkovito odpravlja znake virusne okužbe pri odraslih in otrocih s kroničnim hepatitisom B ali C. Evropska agencija za zdravila (EMA) je ocenila, da koristi pri tem zdravilu odtehtajo tveganja, in je zato priporočila, da se zanj izda dovoljenje za promet.
English: Studies show that Pegasys is effective at clearing signs of viral infection in adults and children with chronic hepatitis B or C.
Slovenian: Študije so pokazale, da zdravilo Pegasys učinkovito odpravlja znake virusne okužbe pri odraslih in otrocih s kroničnim hepatitisom B ali C.
English: What benefits of Pegasys have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Pegasys izkazalo v študijah?
English: For practical information about using Pegasys, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Pegasys naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Peginterferon alfa-2a is similar to interferon alfa-2a, which is widely available in the European Union (EU) as Roferon-A.
Slovenian: Peginterferon alfa-2a je podoben interferonu alfa-2a, ki je v Evropski uniji široko dostopen kot Roferon-A.
English: Pegasys must also not be used in patients with certain liver, heart and other conditions.
Slovenian: Prav tako ga ne smejo uporabljati osebe z nekaterimi boleznimi jeter ali srca in drugimi bolezni.
English: Why is Pegasys approved?
Slovenian: Zakaj je bilo zdravilo Pegasys odobreno?
English: Additional studies showed that peginterferon alfa-2a in combination with telaprevir and ribavirin or with boceprevir and ribavirin significantly increased the proportion of patients who responded to treatment compared with peginterferon alfa-2a plus ribavirin.
Slovenian: Dodatne študije so pokazale, da je peginterferon alfa-2a v kombinaciji s telaprevirom in ribavirinom ali boceprevirom in ribavirinom v primerjavi s peginterferonom alfa-2a in ribavirinom bistveno povečal delež bolnikov, ki so se odzvali na zdravljenje.
English: Finally, a study in 55 children showed similar effectiveness with the combination of Pegasys and ribavirin to that seen in adults treated with Pegasys and ribavirin.
Slovenian: Poleg tega je študija, v katero je bilo vključenih 55 otrok, pokazala podobno učinkovitost kombinacije zdravila Pegasys in ribavirina kot pri odraslih, zdravljenih z zdravilom Pegasys in ribavirinom.
English: Pegasys can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of hepatitis B or C. For further information see the package leaflet.
Slovenian: Predpisovanje in izdaja zdravila Pegasys je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem hepatitisa B oziroma hepatitisa C. Za več informacij glejte navodilo za uporabo.
English: Doses may need to be adjusted for patients who experience side effects.
Slovenian: Pri bolnikih, pri katerih se pojavijo neželeni učinki, je morda treba odmerek prilagoditi.
English: In a study of 151 children with hepatitis B aged 3 and above, 26% of those treated with Pegasys no longer had viral activity in their blood after 24 weeks, compared with 3% of those not given any treatment.
Slovenian: V študiji, v katero je bilo vključenih 151 otrok s hepatitisom B, starejših od treh let, po 24 tednih zdravljenja v krvi ni več imelo virusne dejavnosti 26 % bolnikov, zdravljenih z zdravilom Pegasys, in 3 % bolnikov, ki niso prejemali nobenega zdravila.
English: Another study in 1,149 adult patients showed that the combination of Pegasys with ribavirin was also more effective than Pegasys alone (45% responders at follow-up compared with 24%) and as effective as the combination of interferon alfa-2a and ribavirin (39% responders).
Slovenian: Druga študija s 1 149 odraslimi bolniki je pokazala, da je kombinacija zdravila Pegasys z ribavirinom učinkovitejša od zdravljenja samo z zdravilom Pegasys (45 % odzivnih bolnikov ob kontrolnem pregledu v primerjavi s 24 %) in enako učinkovita kot kombinacija interferona alfa-2a in ribavirina (39 % odzivnih bolnikov).
English: Three studies of 1,441 adult patients showed that more patients taking Pegasys alone had no signs of hepatitis viral activity in their blood after treatment (28 to 39%) than patients taking interferon alfa-2a (8 to 19%).
Slovenian: Tri študije s 1 441 odraslimi bolniki so pokazale, da je bilo število bolnikov, ki po zdravljenju v krvi niso imeli znakov virusne dejavnosti, večje pri tistih, ki so se zdravili samo z zdravilom Pegasys (od 28 do 39 %), kot pri tistih, ki so jemali interferon alfa-2a (od 8 do 19 %).
English: For the full list of all side effects reported with Pegasys, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Pegasys, glejte navodilo za uporabo.
English: Pegasys was more effective than lamivudine (another antiviral medicine) at clearing the hepatitis B virus in 2 studies of 1,372 adult patients.
Slovenian: Zdravilo Pegasys je bilo v dveh študijah s 1 372 odraslimi bolniki pri odstranjevanju virusa hepatitisa B učinkovitejše kot lamivudin (drugo protivirusno zdravilo).
English: For the full list of restrictions with Pegasys, see the package leaflet.
Slovenian: Za celoten seznam omejitev pri uporabi zdravila Pegasys glejte navodilo za uporabo.
English: How does Pegasys work?
Slovenian: Kako zdravilo Pegasys deluje?
English: How is Pegasys used?
Slovenian: Kako se zdravilo Pegasys uporablja?
English: In these studies, the proportions of patients with no signs of viral activity in their blood 6 months after treatment were 32% with Pegasys and 22% with lamivudine among HBeAg-positive patients (those with the common type of the hepatitis B virus).
Slovenian: V teh študijah je bil šest mesecev po zdravljenju med HBeAg-pozitivnimi bolniki (bolniki s pogostim tipom virusa hepatitisa B) delež bolnikov brez znakov virusne dejavnosti v krvi pri zdravilu Pegasys 32 %, pri lamivudinu pa 22 %.
English: Hepatitis B and C are diseases of the liver due to infection with the hepatitis B and C viruses, respectively.
Slovenian: Hepatitisa B in C sta bolezni jeter, ki sta posledica okužbe z virusom hepatitisa B oziroma virusom hepatitisa C. Pri zdravljenju okužbe s hepatitisom B se zdravilo Pegasys običajno uporablja samostojno, pri zdravljenju okužbe s hepatitisom C pa v kombinaciji z drugimi zdravili.
English: The active substance in Pegasys, peginterferon alfa-2a, belongs to the group ‘interferons'.
Slovenian: Zdravilna učinkovina zdravila Pegasys, peginterferon alfa-2a, spada v skupino interferonov.
English: In Pegasys, the interferon alfa-2a has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Slovenian: V zdravilu Pegasys je interferon alfa-2a pegiliran (vezan na snov, imenovano polietilenglikol).
English: Pegasys contains the active substance peginterferon alfa-2a.
Slovenian: Zdravilo Pegasys vsebuje zdravilno učinkovino peginterferon alfa-2a.
English: This summary was last updated in 12-2007.
Slovenian: Povzetek je bil nazadnje posodobljen 12-2007.
English: The main measure of effectiveness was the reduction of pain.
Slovenian: Najpomembnejše merilo učinkovitosti je bilo zmanjšanje bolečine.
English: The marketing authorisation was renewed on 5 February 2003 and on 5 February 2008.
Slovenian: Dovoljenje za promet z zdravilom je bilo podaljšano dne 5. februarja 2003 in 5. februarja 2008.
English: The pain relief may last for up to four months.
Slovenian: Olajšanje bolečin lahko traja do štiri mesece.
English: ©EMEA 2008
Slovenian: Stran 2/2©EMEA 2008
English: QUADRAMET has been studied in 373 patients in three main studies.
Slovenian: Zdravilo QUADRAMET so v treh glavnih študijah raziskovali pri 373 bolnikih.
English: The medicine is given by slow intravenous injection (into a vein) over one minute.
Slovenian: Zdravilo se daje v počasni intravenski injekciji (v veno) v eni minuti.
English: Other information about QUADRAMET:
Slovenian: Druge informacije o zdravilu QUADRAMET:
English: As a result, the radiation brought by the samarium-153 can act locally and help to relieve the bone pain.
Slovenian: Posledica tega je, da žarčenje, ki ga prinese samarij153, lahko deluje lokalno in pomaga lajšati bolečine v kosteh.
English: The European Commission granted a marketing authorisation valid throughout the European Union for QUADRAMET to CIS bio international on 5 February 1998.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom QUADRAMET, veljavno po vsej Evropski uniji, odobrila družbi CIS bio international dne 5. februarja 1998.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Slovenian: kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene študije, na podlagi katerih je oblikoval priporočila glede uporabe zdravila.
English: The following side effects have also been reported: asthenia (weakness), nausea (feeling sick), vomiting, diarrhoea, peripheral oedema (fluid retention), headaches, hypotension (low blood pressure), dizziness, myasthenia (muscle weakness), confusion and sweating.
Slovenian: Poročali so tudi o naslednjih neželenih stranskih učinkih: asteniji (slabotnosti), navzeji (občutku slabosti), bruhanju, driski, perifernih edemih (zadrževanju tekočine), glavobolih, hipotenziji (nizkem krvnem tlaku), vrtoglavici, miasteniji (mišični slabosti), zmedenosti in znojenju.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) QUADRAMET EPAR summary for the public
Slovenian: EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) QUADRAMET Povzetek EPAR za javnost
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite Navodilo za uporabo zdravila (ki je prav tako del EPAR), ali se posvetujte s svojim zdravnikom ali s farmacevtom.
English: The main side effects of QUADRAMET are a reduction in red and white blood cell and platelet counts.
Slovenian: Najpomembnejši neželeni stranski učinki zdravila QUADRAMET so zmanjšanje števila rdečih in belih krvničk ter števila krvnih ploščic.
English: It should not be used in pregnant women or in patients who have had chemotherapy or hemi-body external radiotherapy in the previous six weeks.
Slovenian: Ne sme se ga uporabljati pri nosečnicah ali pri bolnikih, pri katerih je bila v predhodnih šestih tednih opravljena kemoterapija ali zdravljenje z zunanjim obsevanjem polovice telesa.
English: QUADRAMET is a radiopharmaceutical product.
Slovenian: Zdravilo QUADRAMET je radiofarmacevtsko zdravilo.
English: This was measured using various means, such as visual or descriptive scales, analgesic (painkiller) use, and assessment by the doctor.
Slovenian: To so merili na različne načine, na primer z vidno oziroma opisno lestvico, z uporabo analgetikov (zdravil proti bolečinam), in z ocenjevanjem s strani zdravnika.
English: The dose of QUADRAMET is calculated based on the patient's body weight to provide a specific dose of radioactivity (37 mega becquerels per kilogram body weight).
Slovenian: Odmerek zdravila QUADRAMET se izračuna na temelju bolnikove telesne mase, da bi bil zagotovljen določen odmerek radioaktivnosti (37 mega becquerelov na kilogram telesne mase).
English: Before receiving QUADRAMET patients should have a bone scan using bisphosphonates radiolabelled with technetium-99m [99mTc] as markers, to check that their metastases are of the type that QUADRAMET can be used for.
Slovenian: Preden bolniki začnejo prejemati zdravilo QUADRAMET, je treba pri njih opraviti posnetek kosti, pri čemer se kot označevalci uporabijo s tehnecijem-99m [99mTc] radioaktivno označeni bifosfonati, da bi preverili, ali so njihove metastaze take vrste, da se lahko pri njih uporabi zdravilo QUADRAMET.
English: QUADRAMET should only be handled and given by someone who is authorised to use radioactive medicines and after full oncological (cancer) evaluation.
Slovenian: Z zdravilom QUADRAMET lahko rokuje in ga daje le nekdo, ki je pooblaščen za uporabo radioaktivnih zdravil in po popolni onkološki oceni (oceni rakavega obolenja).
English: What is the risk associated with QUADRAMET?
Slovenian: Kakšna tveganja so povezana z zdravilom QUADRAMET?
English: QUADRAMET should not be used in people who may be hypersensitive (allergic) to EDTMP or to phosphonates (similar chemical compounds).
Slovenian: Zdravila QUADRAMET se ne sme uporabljati pri ljudeh, ki utegnejo biti preobčutljivi za (alergični na) EDTMP ali fosfonate (podobne kemične spojine).
English: What benefit has QUADRAMET shown during the studies?
Slovenian: Kakšne koristi je zdravilo QUADRAMET izkazalo med raziskavami?
English: Patients who respond to QUADRAMET generally have relief of their pain within one week of treatment.
Slovenian: Pri bolnikih, ki se odzivajo na zdravljenje z zdravilom QUADRAMET, pride do lajšanja bolečin v enem tednu zdravljenja.
English: It is a complex (a type of chemical) made up of a radioactive element, samarium-153 (153Sm), bound to another chemical called ‘ethylene diamine tetra methylene phosphonic acid'
Slovenian: Gre za spojino (vrsta kemične snovi), sestavljeno iz radioaktivnega elementa samarija-153 (153Sm), ki je vezan na drugo kemično snov, imenovano etilen diamin tetrametilen fosfonska kislina (EDTMP).
English: Osteoblastic metastases are a type of bone metastasis where new bone tissue grows rapidly.
Slovenian: Osteoblastne metastaze so vrsta kostnih metastaz, pri katerih kostno tkivo hitro raste.
English: When QUADRAMET is injected into a patient, the complex is distributed around the body via the bloodstream.
Slovenian: Ko se zdravilo QUADRAMET vbrizga v bolnikovo telo, se spojina porazdeli po telesu prek krvnega obtoka.
English: In one of the studies, which involved patients with bone metastases from prostate cancer, the patients' use of opioid analgesics (such as morphine) was also reduced following treatment with QUADRAMET.
Slovenian: V eni izmed študij, ki je vključevala bolnike s kostnimi metastazami zaradi rakavega obolenja prostate, je po zdravljenju z zdravilom QUADRAMET prišlo tudi do zmanjšanja uporabe opiatnih analgetikov (kot je na primer morfin).
English: QUADRAMET was effective in providing pain relief from osteoblastic bone metastases, and, where it was compared with placebo, more effective than placebo.
Slovenian: Zdravilo QUADRAMET je bilo učinkovito pri lajšanju bolečine zaradi osteoblastnih kostnih metastaz, kadar pa so ga primerjali s placebom, se je izkazalo kot učinkovitejše od placeba.
English: The Committee recommended that QUADRAMET be given marketing authorisation.
Slovenian: Priporočil je podelitev dovoljenja za promet z zdravilom QUADRAMET.
English: In two of these, the effectiveness of QUADRAMET was compared with that of placebo (a dummy treatment).
Slovenian: V dveh izmed teh študij so učinkovitost zdravila QUADRAMET primerjali z učinkovitostjo placeba (zdravilo brez zdravilne učinkovine).
English: QUADRAMET should not be used at the same time as any chemotherapy that affects the bone marrow or at the same time as other bisphosphonate medicines if these can interact with the way QUADRAMET fixes to bone metastases.
Slovenian: Zdravila QUADRAMET se ne sme uporabljati sočasno z nobeno kemoterapijo, ki vpliva na kostni mozeg, niti sočasno z drugimi bifosfonatnimi zdravili, če ta lahko vplivajo na način, kako se zdravilo QUADRAMET veže na kostne metastaze.
English: QUADRAMET is only used in bone metastases that can take up a type of chemical called bisphosphonates, as this means that the metastases will also take up QUADRAMET.
Slovenian: Zdravilo QUADRAMET se uporablja samo pri kostnih metastazah, ki lahko absorbirajo določeno kemično snov, imenovano bifosfonati, kajti to pomeni, da bodo metastaze absorbirale tudi zdravilo QUADRAMET.
English: For the full list of all side effects reported with QUADRAMET, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila QUADRAMET, glejte Navodilo za uporabo.
English: QUADRAMET is used to relieve bone pain in patients with multiple painful osteoblastic skeletal metastases (when cancer has spread to the bones).
Slovenian: Zdravilo QUADRAMET se uporablja za lajšanje bolečin v kosteh pri bolnikih z množičnimi bolečimi osteoblastnimi kostnimi metastazami (ko se je rakavo obolenje razširilo v kosti).
English: Its active substance is samarium [153Sm] lexidronam pentasodium.
Slovenian: Zdravilna učinkovina v njem je samarijev [153Sm] leksidronam pentanatrij.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that QUADRAMET's benefits are greater than its risks for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila QUADRAMET pri lajšanju bolečin v kosteh pri bolnikih z množičnimi bolečimi osteoblastnimi kostnimi metastazami večje od z njim povezanih tveganj.
English: Why has QUADRAMET been approved?
Slovenian: Zakaj je bilo zdravilo QUADRAMET odobreno?
English: The full EPAR for QUADRAMET is available here.
Slovenian: Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo QUADRAMET je na voljo tukaj.
English: Because EDMTP has a high affinity for bone tissue, it accumulates in the bone, especially in areas of rapid bone growth such as osteoblastic metastases.
Slovenian: Ker ima EDTMP veliko afiniteto do kostnega tkiva, se kopiči v kosteh, še posebno v predelih
English: How has QUADRAMET been studied?
Slovenian: Kako je bilo zdravilo QUADRAMET raziskano?
English: QUADRAMET is a solution for injection containing the active substance samarium [153Sm]
Slovenian: Zdravilo QUADRAMET je raztopina za injiciranje, ki vsebuje zdravilno učinkovino [153Sm]samarij leksidronam, pentanatrijeva sol.